GPP
NKTR icon

Great Point Partners’s Nektar Therapeutics NKTR Stock Holding History

Great Point Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,667
Closed -$539K – 39
2022
Q1 		$539K Sell
6,667
-6,926
-51% -$1.03M 0.13% 28
2021
Q4 		$2.75M Buy
+13,593
New +$2.95M 0.61% 32

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Great Point Partners's NKTR Position: Q1 2026 in Review

Great Point Partners increased its Nektar Therapeutics (NKTR) stake by 50% in Q1 2026, buying an estimated $6.02M and bringing the position to 316,453 shares worth $22.8M. The position accounts for 5.23% of the portfolio, ranked #6.

Great Point Partners first reported a position in NKTR in Q3 2019 and has held it in 7 quarters since. The position peaked at $38.7M in Q3 2019. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Great Point Partners held 316,453 shares of Nektar Therapeutics worth $22.8M as of Q1 2026.
  • Great Point Partners bought 105,721 Nektar Therapeutics shares in Q1 2026, an estimated $6.02M.
  • Nektar Therapeutics made up 5.23% of Great Point Partners's portfolio in Q1 2026, its #6 holding.
  • Great Point Partners first reported a position in Nektar Therapeutics in Q3 2019 and has held it in 7 quarters since.
  • Great Point Partners's Nektar Therapeutics position peaked at $38.7M in Q3 2019.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.